Sitfel Nicolaus Initiates Coverage of Abbott with a “Buy” Rating (ABT)
Sitfel Nicolaus reported on Friday that they have began coverage of health care product company, Abbott Laboratories(ABT).
The firm has initiated coverage of ABT with a “Buy” rating and $40 price target. This price target suggests a 12% increase from the stock’s current price of $34.95.
Analysts have given the company the “Buy” rating and price target based on the company’s ability to maintain consistent earnings growth.
Abbott Laboratories shares were up 30 cents, or 0.86% during Friday morning trading. The stock has increased 26% in the past year.
The Bottom Line
Shares of Abbott Laboratories(ABT) have a 1.60% yield, based on Friday morning’s price of $34.95.
Abbott Laboratories(ABT) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
Get FREE Dividend Tips, Updates & MoreWe respect your privacy
- Powerful dividend insights sent every weekday morning
- Gain instant access to actionable investing tips
- Strategically grow your portfolio’s profitability